---
layout: default
title: Activated Charcoal Anemone Pulsatilla Antimony Tri
parent: 僅模型預測 (L5)
nav_order: 180
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Anemone Pulsatilla Antimony Tri
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Preparation: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate consists of a 27-component homeopathic mixture (including Arsenicum Album, Lachesis Muta Venom, Nux Vomica, Sulfur, Mercury, and others), with no registered indication on record in any market queried. The TxGNN model returned **no predicted indications** for this entry, and no clinical trial or literature evidence is available to support any repurposing direction. This record cannot advance to a standard evaluation without fundamental data remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model operates by mapping a drug to a DrugBank node and traversing the knowledge graph to identify disease nodes with high repurposing probability. This pipeline requires:

1. A resolvable DrugBank ID for the compound
2. A single, unified chemical or biological entity (not a mixture of 27 ingredients)
3. A known mechanism of action that can be encoded as graph edges

None of these prerequisites are met for this record. The "drug" submitted is a list of 27 separate substances — many of which are classical homeopathic dilutions (e.g., Arsenicum Album, Lachesis Muta Venom, Mercurius, Sulfur, Nux Vomica Seed) rather than a single pharmacological agent. Because the query string was passed as a concatenated INN list, no DrugBank match was found, and the knowledge graph could not anchor a prediction.

Additionally, homeopathic preparations as a class typically lack quantifiable pharmacokinetic or pharmacodynamic data, which further prevents standard MOA-based graph traversal.

---

## US Market Information

No authorizations found. This compound has not been registered with the FDA under any NDA or homeopathic OTC monograph associated with this specific combination.

---

## Safety Considerations

No structured safety data is available for this multi-ingredient combination. Please refer to individual ingredient package inserts and relevant pharmacopoeia monographs for component-level warnings. Note that several individual ingredients (Arsenic Trioxide, Mercury, Lachesis Muta Venom, Strychnos Nux-Vomica Seed) carry well-established toxicological profiles at pharmacological doses.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This record cannot be evaluated as a drug repurposing candidate because it lacks a resolvable drug identity, a DrugBank ID, any regulatory approval, and any TxGNN prediction output. The compound structure — a 27-ingredient homeopathic mixture — is incompatible with the current single-entity TxGNN pipeline.

**To proceed, the following is needed:**

- **Clarify evaluation intent:** Determine whether the goal is to evaluate one specific active ingredient from this list (e.g., Arsenic Trioxide, which has an approved oncology indication) or the mixture as a whole.
- **Decompose the record:** If evaluating individual components, split into separate candidates and resubmit each with its own DrugBank ID and INN.
- **Obtain a DrugBank ID:** At minimum one DrugBank-resolvable entity is required to trigger graph-based prediction.
- **Resolve regulatory origin:** Identify which country registered or submitted this combination, and retrieve the corresponding product monograph or indication text.
- **MOA documentation:** Until a specific active entity is isolated, mechanism-of-action analysis cannot proceed.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

